Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex

Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex

Xiang Wang,1 Yuanqi Hua,1 Guangya Xu,1 Senyi Deng,1 Daoke Yang,2 Xiang Gao1 1Department of Neurosurgery, Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu 610041,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wang X, Hua Y, Xu G, Deng S, Yang D, Gao X
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Glioma
Gene-therapy
EZH2
MPEG-PCL
DOTAP.
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/b03f34c36f3246599949d6f393b48210
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:b03f34c36f3246599949d6f393b48210
record_format dspace
spelling oai:doaj.org-article:b03f34c36f3246599949d6f393b482102021-12-02T05:27:25ZTargeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex1178-2013https://doaj.org/article/b03f34c36f3246599949d6f393b482102019-04-01T00:00:00Zhttps://www.dovepress.com/targeting-ezh2-for-glioma-therapy-with-a-novel-nanoparticle-sirna-comp-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Xiang Wang,1 Yuanqi Hua,1 Guangya Xu,1 Senyi Deng,1 Daoke Yang,2 Xiang Gao1 1Department of Neurosurgery, Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu 610041, China; 2Tumor Hospital of First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China Background: For the past few years, gene-therapy has recently shown considerable clinical benefit in cancer therapy, and the applications of gene therapies in cancer treatments continue to increase perennially. EZH2, an ideal candidate for tumor gene therapy, plays an important role in the tumorigenesis. Methods: In this study, we developed a novel gene delivery system with a self-assembly method by Methoxy polyethylene glycol-polycaprolactone (MPEG-PCL) and DOTAP(DMC). And EZH2si-DMC was used to research anti-glioma both in vitro and in vivo. Results: DMC with zeta-potential value of 36.7 mV and size of 35.6 nm showed good performance in the delivery siRNA to glioma cell in vitro with high 98% transfection efficiency. EZH2si-DMC showed good anti-glioma effect in vitro through inducing cell apoptosis and inhibiting cell growth. What’s more, treatment of tumor-bearing mice with DMC-EZH2si complex had significantly inhibited tumor growth at the subcutaneous model in vivo by inhibiting EZH2 protein expression, promoting apoptosis and reducing proliferation. Conclusion: The EZH2 siRNA and DMC complex may be used to treat the glioma in clinical as a new drug. Keywords: glioma, gene therapy, EZH2, MPEG-PCL, DOTAP, tumorigenesisWang XHua YXu GDeng SYang DGao XDove Medical PressarticleGliomaGene-therapyEZH2MPEG-PCLDOTAP.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 2637-2653 (2019)
institution DOAJ
collection DOAJ
language EN
topic Glioma
Gene-therapy
EZH2
MPEG-PCL
DOTAP.
Medicine (General)
R5-920
spellingShingle Glioma
Gene-therapy
EZH2
MPEG-PCL
DOTAP.
Medicine (General)
R5-920
Wang X
Hua Y
Xu G
Deng S
Yang D
Gao X
Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex
description Xiang Wang,1 Yuanqi Hua,1 Guangya Xu,1 Senyi Deng,1 Daoke Yang,2 Xiang Gao1 1Department of Neurosurgery, Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu 610041, China; 2Tumor Hospital of First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China Background: For the past few years, gene-therapy has recently shown considerable clinical benefit in cancer therapy, and the applications of gene therapies in cancer treatments continue to increase perennially. EZH2, an ideal candidate for tumor gene therapy, plays an important role in the tumorigenesis. Methods: In this study, we developed a novel gene delivery system with a self-assembly method by Methoxy polyethylene glycol-polycaprolactone (MPEG-PCL) and DOTAP(DMC). And EZH2si-DMC was used to research anti-glioma both in vitro and in vivo. Results: DMC with zeta-potential value of 36.7 mV and size of 35.6 nm showed good performance in the delivery siRNA to glioma cell in vitro with high 98% transfection efficiency. EZH2si-DMC showed good anti-glioma effect in vitro through inducing cell apoptosis and inhibiting cell growth. What’s more, treatment of tumor-bearing mice with DMC-EZH2si complex had significantly inhibited tumor growth at the subcutaneous model in vivo by inhibiting EZH2 protein expression, promoting apoptosis and reducing proliferation. Conclusion: The EZH2 siRNA and DMC complex may be used to treat the glioma in clinical as a new drug. Keywords: glioma, gene therapy, EZH2, MPEG-PCL, DOTAP, tumorigenesis
format article
author Wang X
Hua Y
Xu G
Deng S
Yang D
Gao X
author_facet Wang X
Hua Y
Xu G
Deng S
Yang D
Gao X
author_sort Wang X
title Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex
title_short Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex
title_full Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex
title_fullStr Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex
title_full_unstemmed Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex
title_sort targeting ezh2 for glioma therapy with a novel nanoparticle–sirna complex
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/b03f34c36f3246599949d6f393b48210
work_keys_str_mv AT wangx targetingezh2forgliomatherapywithanovelnanoparticlendashsirnacomplex
AT huay targetingezh2forgliomatherapywithanovelnanoparticlendashsirnacomplex
AT xug targetingezh2forgliomatherapywithanovelnanoparticlendashsirnacomplex
AT dengs targetingezh2forgliomatherapywithanovelnanoparticlendashsirnacomplex
AT yangd targetingezh2forgliomatherapywithanovelnanoparticlendashsirnacomplex
AT gaox targetingezh2forgliomatherapywithanovelnanoparticlendashsirnacomplex
_version_ 1718400435430096896

Ejemplares similares